The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 24, 2018

Filed:

Sep. 22, 2016
Applicant:

Novartis Ag, Base, CH;

Inventors:

Michaela Kneissel, Basel, CH;

Vito Guagnano, Basel, CH;

Diana Graus Porta, Basel, CH;

Simon Wöhrle, Vienna, AT;

Assignee:

Novartis AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61K 33/42 (2006.01); A61K 33/06 (2006.01); A61K 38/17 (2006.01); A61K 38/29 (2006.01); A61K 31/59 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/59 (2013.01); A61K 33/06 (2013.01); A61K 33/42 (2013.01); A61K 38/1709 (2013.01); A61K 38/29 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.


Find Patent Forward Citations

Loading…